Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
Physician‐assessed changes in clinical signs · children with eczema
1 finding from 1 review
Secondary outcome: quality of life · children with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: clinical flare · children with eczema
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
1 finding from 1 review
Quality of life measure · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Reduction in pain intensity · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (not reported) · patients with trigeminal neuralgia
1 finding from 1 review
Relief of pain · patients with trigeminal neuralgia
Proparacaine hydrochloride 0.5% eye drops showed no clear difference in immediate improvement in pain relief Number of participants improved… compared with placebo (low certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 4‐5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
1 finding from 1 review